Unites Global Community to Free the World of Lupus through the Power of Science NEW YORK, NY. May 1. – The Lupus Research Alliance today kicks off its Breaking through for YOU campaign to mark its inaugural Lupus Awareness Month. The newly merged organization’s first campaign draws the world’s attention to the urgent need to […] READ MORE
NEW YORK, NY – April 4, 2017. Nearly 300 prominent women and men from New York’s fashion, society, entertainment, publishing, philanthropic and lupus communities came together today to raise funds for lupus research. The 8th annual Lupus Handbag Luncheon & Silent Auction was the first hosted by the Lupus Research Alliance, formed by the recent merger […] READ MORE
10 New Grants, 10 New Insights The path to safe and effective treatments and ultimately a cure lies in bold, pioneering research. The Lupus Research Alliance Novel Research Grants, the proven platform for innovation, make discovery and scientific progress possible. “Standing on a 16-year foundation of documented success, the Novel Research Grants bring new insight […] READ MORE
Demonstrates the Power of Patient Advocacy Lupus patients will have a new medical research program at work for them in the future if Bill H.R. 1301 passed today by the House of Representatives becomes law. The House approved the Fiscal 2017 Defense Appropriations Conference Report which designates $5 million for new peer-reviewed lupus research under […] READ MORE
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced top-line results from its Phase IIb AURA-LV (AURA) study in lupus nephritis (LN). At 48 weeks, the trial met the complete and partial remission (“CR”/ “PR”) endpoints, demonstrating statistically significantly greater CR […] READ MORE
The Lupus Research Alliance proudly announces that the last major hurdle to the 21st Century Cures Act has been cleared as the U.S. Senate joined the House of Representatives in voting for its passage by an overwhelming majority vote of 94 to 5. Capping two years of consistent advocacy work, the bill is now cleared […] READ MORE
The Lupus Research Alliance commends the U.S. House of Representatives for passing the bipartisan House Amendment last night 392-26, which updated the 21st Century Cures Act, intended to spur the development of new medical treatments in many disease areas including lupus. Having worked hard over the past several years to voice the needs of the […] READ MORE
NEW YORK, NY – The newly merged Lupus Research Alliance celebrated its debut at the Inaugural Gala, uniting the three world leaders in lupus research as the driving force for better treatments and a cure. In just one night, the country’s largest lupus fundraising event raised over $2.5 million – with every dollar going directly to support lupus […] READ MORE
NEW YORK, NY – The newly merged Lupus Research Alliance raised an unprecedented $3 million for lupus research through its 2016 Walk with Us to Cure Lupus program and TCS NYC Marathon team. By year’s end, the national Walk program will reach approximately $33.5 million raised since its inception in 2002. Every penny – 100% – raised goes […] READ MORE
NEW YORK, NY — The Lupus Research Alliance launched a bold initiative, the Lupus Clinical Investigators Network (LuCIN) to accelerate the identification and development of new therapies to treat lupus. Comprised of leading lupus experts at 58 academic research centers throughout North America, LuCIN provides a coordinated framework to test potential new treatments quickly and cost-effectively while upholding the highest […] READ MORE
Crowd-sourcing, Literature Review and Big Data Analysis Identify Promising Lupus Treatments NEW YORK, NY –- New results published in the professional journal Lupus demonstrate the effectiveness of an innovative system developed to identify promising treatments for lupus among existing drugs approved for use in other diseases. Funded by the Lupus Research Alliance and the John and Marcia […] READ MORE
First Promising Phase II Data in Lupus Nephritis NEW YORK, NY — The Lupus Research Alliance congratulates Aurinia Pharmaceuticals on achieving the first positive Phase II study of a greatly needed potential treatment for lupus nephritis. Up to 60% of people with lupus develop lupus nephritis, a devastating complication that can cause kidney failure and […] READ MORE
